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INTRODUCTION 
Each year, over 250 million people 
worldwide develop urinary tract infection 
(UTI).
1
 The UTIs are the second leading 
infection, after respiratory diseases, in 
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ABSTRACT 
Background and aims: Urinary tract infections (UTIs) are one of the most common and the 
second leading infections, after respiratory tract infections, in women. Currently, various 
chemical drugs are used to prevent the UTIs. Chemical drugs may cause antibiotic resistance 
and cause resistant strains likely grow in the long-term treatment with antibiotics. The aim of 
this study was to investigate the effect of Cornus mas in preventing recurrent UTIs in women 
aged 15-45 years referring to Ayatollah Kashani Hospital Clinic in Shahrekord. 
Methods: This experimental study (Parallel Design and Triple-blind) was conducted on  
42 women aged 15-45 years referring to Ayatollah Kashani Hospital Clinic of Shahrekord 
and diagnosed with chronic cystitis. The exclusion criteria were neurogenic bladder, 
genitourinary system anatomical abnormalities (hydronephrosis, ureterocele stone, etc), and 
bacterial resistance. The women were randomly assigned to 2 groups. At baseline, the 
women were examined for any functional and anatomical disorders and if it was necessary, 
they underwent ultrasound. After the current UTIs were treated and the women clinically 
recovered, one group was administered with Cornus mas tablet 500 mg and another group 
administered with placebo for 6 months. All the women were followed up for 6 months. 
Every 2 months, the patients were clinically examined and their urine cultures were 
investigated for the clinical signs of cystitis. As the symptoms of the UTIs occur, the 
patients were recommended to refer for repeated urine culture. All patients (42 women) 
completed the study. 
Results: In our study, no significant difference was observed between the groups in terms of 
recurrent UTI recurrence,   although there were differences (P>0.005). Positive urine culture 
in Cornus mas group was 19% and in placebo was 33.4%. In terms of dysuria in 6 months 
and the second time, there was a significant difference between placebo and Cornus mas 
(P=0.004) Dysuria in Cornus mas group was 14.2% and in placebo was 56.2%. 
Conclusion: Cornus mas can decrease dysuria and frequent urination in patients with 
recurrent UTIs, so it can be used in the treatment of these patients. 
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women, older people, and infants.
2
 These 
infections are caused due to urinary tract 
microorganisms, and can be symptomatic or 
asymptomatic. Escherichia coli, followed by 
Proteosolgaris, is the leading bacterial  
cause of the UTIs. Klebsiella pneumoniae, 
Staphylococcus epidermidis, Enterobacter, 
Citrobacter, and Pseudomonas aeruginosa can 
be other bacterial causes of the UTIs.
3
 In 
symptomatic UTIs, certain symptoms may be 
seen, including frequent urination, dysuria, 
urinary incontinence, forcing urine out,  
strong-smelling urine, and in some cases, 
fever.
4
 According to the available evidence, 
the incidence of ampicillin and amoxicillin 
resistance is 100% in the gram-negative bacilli 
from Enterobacteriaceae. Moreover, the 
resistance of different Staphylococcal strains 
has been reported to be 70%-90%.
2
 The side 
effects due to antibiotics and increasing 
antibiotic resistance have led to increased 
attention to herbal drugs and nature-based 
antimicrobial agents. 
Cornus mas (C. mas) is from family 
Valerian and rich in anthocyanins, which  
can be the cause of its pharmacological 
properties, including antioxidant, anti-allergy, 
antibacterial, and anti-inflammatory.
5
 
Uropathogenic adhesion to urinary  
tract cells is the first step of the UTI 
pathogenesis.
6
 The anti-adhesion property of 
C. mas can contribute to the prevention of 
the UTIs either directly through Escherichia 
coli adhesion to urothelial cells or through 
decreased bacterial adhesion in stool. Recent 
studies have demonstrated that regular use 
of C. mas is helpful for the patients with 
UTIs who have antibiotic resistance.
7
 
C. mas juice has become popular as a 
natural alternative for the prevention of 
urinary tract infections (UTIs), which have a 
high incidence in women and elderly 
persons. Moreover, C. mas juice has shown 
efficacy in reducing UTIs in women with 
recurrent episodes and in reducing 
bacteriuria in elderly persons. Clinical 
benefits are associated with chronic use 
(months) and with a regular frequency of 
consumption (daily).
8
 Studies have shown 
that the prophylactic nature of C. mas juice 
is a result of inhibition of the adhesion of 
bacterial fimbriae to uroepithelial cells, 
rather than because of urinary acidification.
9
 
C. mas juice also has shown a beneficial 
effect against drug-resistant bacteria.
10
 The 
anti-adhesion property of C. mas has been 
reported to persist for 2-10 hours after use.
11
 
Anticianidine, a compound found in C. mas, 
can prevent the pathogens adhesion to 
urothelial cells. Some studies have reported 
that C. mas can decrease the incidence of 
recurrent UTIs and some others have found 
no (predictable) effects of C. mas in the 
incidence of the recurrent UTIs.
12
 
Moreover, inconsistent findings have 
been obtained on C. mas effects on the 
UTIs. Regarding the high prevalence of the 
UTIs in the community and because the 
people of Chaharmahal and Bakhtiari 
province have long been using plants to treat 
diseases, especially the UTIs, we conducted 
this study to investigate the effects of C. mas 
on the recurrent UTIs in women aged 15-45 
years. Study of Chypsvn and colleagues on 
the effects of prophylactic C. mas showed in 
urinary tract infections C. mas juice was 
effective in reducing urinary tract infection 
but has no effect on other variables, because 
gastrointestinal side effects for patients after 
consumption of C. mas juice, that was left 
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taking it, So, it was used in this study C. mas 
tablet form.
13
 
 
METHODS 
This randomized clinical trial was done 
on 2 groups (each group: 21) of 15-45 years 
old women with different weight and 
recurrent cystitis who referred to Clinic of 
Shahrekord Kashani hospital in 2013 that 
sample size was determined using the 
software Stata and according to the available 
studies. The subjects were matched in view 
of the year's old, length of disease, level of 
education, social category, place of life and 
quality of individual health. Then, using 
SPSS the subjects were allocated to  
groups randomly, Patients, sampling and 
analyzer of data were blinded. This study 
was approved by ethical committee of 
Shahrekord University of Medical Sciences 
and was done with ethical code (4-3-93) and 
code of Iranian randomized clinical trial 
center (IRCT2015111625072N1). Written 
informed consent was obtained from all 
subjects and other ethical principals were 
achieved. Before the subjects were enrolled 
in the study, their anatomical and functional 
problems were examined and sonography 
and intravenous pyelography were done if it 
was necessary. The subjects with anatomical 
problems of urinary system (kidney stone, 
urethrocel, hydronephrosis) and dysfunction 
of urinary system (neurogenic bladder) were 
excluded from study. Because of differences 
in the number of subjects' intercorsing and 
prevention of study error, it was applied a 
long time and low dose of consuming the 
drug in this study. After treatment of 
primary urinary infection and promoting 
clinical status, we gave the C. mas tablet 
(500 mg, Based on existing studies) to the 
first group for 6 month nightly and the 
placebo to the second group for 6 months 
nightly. For extraction, 30 kg of C. mas 
prepared by the city of Qazvin, Iran was 
dried in shadow gradually and converted to 
powder by mechanical milling, and then the 
powder was mixed with ethanol 70%  
(1 vs. 5) by maceration method for 4 days. 
The extraction was passed from filter paper 
and was concentrated under vacuum by 
rotary operator machine. Then, concentrate 
extract was knead with calcium triphosphate 
and dried in granulation form. After the 
standardization by assessing the anthocyanin 
content, we filled the tablets with C. mas 
granule. For making the placebo, it was 
provided dough from starch and starch paste 
and converted to dried granule, and then the 
same tablets were filled by the dried herb 
extract.
14
 The patients were followed for  
6 months and stayed on clinical examination, 
urine analyzing, urine culturing and  
assessing for cystitis clinical sign (dysuria, 
incontinency and suprapubic pain). The 
patients with positive test were excluded 
from the study and treated for their recurrent 
infection and recommended them for 
repeating urine culture whenever if infection 
sign was seen. During the months 2,4,6, after 
urine culturing, urine incontinence, dysuria, 
abdominal pain were assessed and signed in 
the checklist by the researcher. The data were 
calculated and analyzed with chi-square test 
using SPSS software. 
 
RESULTS 
In the C. mas-treated group, 4(19%) people 
developed recurrent UTI and in the placebo 
group, 7(33.4%) did. Although there were some 
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differences in the mean incidence of the 
recurrent UTIs during the 6 months, chi-square 
test indicated no significant difference in the 
incidence of the recurrent UTIs between the  
2 groups (P>0.005). Chi-square test indicated no 
significant difference in the urine culture in the 
first, the second, and the third two-month 
periods between the 2 groups (P>0.005)  
(Table 1, Figure 1). 
It should be noted, All participants 
continued to the end of the intervention  
(n= 21 per group). 
 
Table 1: The frequency distribution of the urine culture in the groups of the study 
 
P 
Cornus mas Placebo Groups 
 
Variables 
Negative urine 
culture 
Positive urine 
culture 
Negative urine 
culture 
Positive urine 
culture 
0.159 17(81%) 4(19%) 14(66.6%) 7(33.4%) During 6 months 
0.463 17(81%) 4(19%) 16(76.2%) 5(23.2%) The first 2 months 
0.362 21(100%) 0(0%) 20(95.2%) 1(4.8%) The second 2 months 
0.362 21(100%) 0(0%) 20(95.2%) 1(4.8%) The third 2 months 
P<0.005 was considered the level of significance. 
 
 
Figure 1: The frequency distribution of the 
urine culture in the groups of the study in  
6 months 
Moreover, there were some 
differences in the frequent urination 
between the 2 groups, but chi-square 
test indicated no significant difference 
in the frequent urination during the  
6 months between the 2 groups 
(P>0.005). During the 6 months, in the 
placebo group, 38% developed frequent 
urination and in the C. mas-treated 
group, 22.4% did. In other words, the 
frequent urination decreased in the  
C. mas-treated group by 15.6% 
compared to the placebo group (Table 2, 
Figure 2). 
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Table 2: The frequency distribution of the frequent urination in the groups of the study 
 
P 
Cornus mas Placebo Groups 
 
Variables 
Positive frequent 
urination 
Negative frequent 
urination 
Positive frequent 
urination 
Negative frequent 
urination 
351.0 8(38%) 13(62%) 5(22.4%) 16(76.2%) During 6 months 
0.852 3(14.2%) 18(85.8%) 2(9.6%) 19(90.4%) The first 2 months 
0.852 3(14.2%) 18(85.8%) 2(9.6%) 19(90.4%) The second 2 months 
0.325 4(19%) 17(81%) 2(9.6%) 19(90.4%) The third 2 months 
P<0.005 was considered the level of significance. 
 
 
Figure 2: The frequency distribution of the 
frequent urination in the groups of the study 
in 6 months 
In addition, there were some differences 
in abdominal pain between the 2 groups of 
the study, but chi-square test indicated no 
significant difference in abdominal pain 
between the 2 groups during the 6-month 
period (P>0.005). During the 6 months, in the 
placebo group, 19% of the women developed 
abdominal pain and in the C. mas-treated 
group, 4.8% did. 
There were some differences in dysuria 
between the first and the second 2 months, 
but chi-square test indicated no significant 
difference in dysuria between the first and the 
second 2 months (P>0.005). Chi-square test 
indicated a significant difference in dysuria in 
the second 2 months (the fourth month) and 
during the 6-month months between the 
placebo group and the C. mas-treated group 
(P<0.005). Within the 6 months, in the 
placebo group, 57.2% of the women 
developed dysuria and in the C. mas-treated 
group, 14.2% did. More clearly, dysuria 
decreased in the C. mas-treated group  
by 43% compared to the placebo group 
(Table 3, Figure 3). 
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Table 3: The frequency distribution of dysuria in the groups of the study 
P Cornus mas Placebo Groups 
Variables Positive dysuria Negative dysuria Positive dysuria Negative dysuria 
0.004 12(57.2%) 9(42.8%) 3(14.2%) 18(85.8%) During 6 months 
0.116 6(28.6%) 15(71.4%) 2(9.6%) 19(90.4%) The first 2 months 
0.038 6(28.6%) 15(71.4%) 1(4.8%) 20(95.2%) The second 2 months 
0.078 5(22.4%) 16(76.2%) 1(4.8%) 20(95.2%) The third 2 months 
P<0.005 was considered the level of significance. 
 
 
Figure 3: The frequency distribution of 
dysuria in the groups of the study in 6 
months 
 
DISCUSSION 
This study was conducted to compare 
the effects of C. mas tablet and placebo in 
preventing the recurrent UTIs in the women 
aged 15-45 years referring to Ayatollah 
Kashani Hospital Clinic of Shahrekord. The 
UTIs are one of the most common reasons 
for referring of the outpatients to health care 
centers. These infections may lead to 
hospital stay due to critical conditions or an 
underlying debilitating disease in the patient. 
In the present study on 42 women with 
recurrent UTIs during 6 months, there were 
some differences in the recurrent UTIs 
between the 2 groups yet statistically  
non-significant. The urinary tract symptoms 
also were studied, and there was a 
statistically significant difference in dysuria 
between the placebo and the C. mas-treated 
groups. In Kontiokari et al study on  
150 women with recurrent UTIs, the 
incidence of the UTIs decreased after  
6 months of using concentrated C. mas. In 
this study, the overall incidence of the 
recurrent UTIs during 12 months was 
statistically significantly different between 
the case and the control groups (P=0.048). 
In the case group, treated with C. mas 
extract for 6 months, 16% of the patients 
developed recurrent UTI at least once, while 
in the control group, 36% did. The incidence 
of the recurrent UTIs decreased in the case 
group by 20% compared to the control 
group, which is inconsistent with our 
study.
15
 This may be due to conducting a 
study during a longer period of time 
compared to our study. Moreover, 
Takahashi et al investigated the effects of  
C. mas juice in preventing the recurrent 
UTIs in a small number of women who used 
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C. mas juice for 24 weeks, and found the  
C. mas juice to be effective in preventing 
these infections.
6
 However, in the present 
study, the tablets of C. mas were used and 
no significant difference was seen in the 
incidence of the recurrent UTIs between the 
2 groups. This inconsistency may be due to 
the differences in the concentrations of 
effective compounds between the C. mas 
tablet and pure juice. 
Hess et al investigated the effects of  
C. mas tablet in preventing the UTIs in 
spinal cord lesion (SCL) patients with 
neurogenic bladder. The patients were 
randomly assigned to two groups, the 
controls and the cases, and administered 
with placebo and the C. mas tablet, 
respectively, for 6 months. After 6 months, 
the clinical symptoms of the UTIs decreased 
probably due to taking the C. mas tablets 
and even, compared to the controls, the 
frequency of the UTIs incidence per year 
decreased.
16
 Similarly, in our study, the  
C. mas tablet was used and the urinary tract 
symptoms decreased, partly in the case 
group compared to the controls, but the 
recurrent UTIs did not decrease significantly. 
Barbosa-Cesnik et al investigated the effects 
of C. mas juice on the risk of the recurrent 
UTIs incidence in 319 female university 
students. In this study, the incidence of the 
recurrent UTIs did not decrease in the group 
who used C. mas juice twice a day 
compared to the placebo-receiving group 
during a period of 6 months.
17
 In our study, 
C. mas tablet was used, and consistent with 
Barbosa-Cesnik et al study, no significant 
decrease was seen in the recurrent UTIs 
between the 2 groups of the study. In a study 
on 48 SCL patients with neurogenic bladder, 
22 patients received placebo and 26 were 
administered with the C. mas tablet. The  
C. mas tablet was found to cause bacteriuria 
and pyuria in the SCL patients.
18
 
In another study on SCL patients with 
neurogenic bladder, C. mas tablet had no 
effect in reducing bacterial colony counts, 
pyuria, and the incidence of the UTIs in these 
patients.
19
 Similarly, the present study 
demonstrated that use of C. mas tablet caused 
no decrease in the recurrent UTIs. In the 
current study, the incidence of recurrent UTIs 
was 19% and 33.4% in the C. mas-treated and 
the placebo groups, respectively, with no 
significant difference. Uropathogenic 
adhesion to urinary tract cells is considered the 
first step of the UTIs pathogenesis. The  
anti-adhesion property of C. mas can prevent 
the UTIs through 2 mechanisms, directly 
through E. coli adhesion to urothelial cells or 
through helping to decrease bacterial adhesion 
in stool. Because the anti-adhesion property of 
C. mas can persist for 2-10 hours after use, the 
incidence of the recurrent UTIs is more likely 
to decrease if each day 2 C. mas tablets are 
used.
11
 Regarding other studied variables, 
such as frequent urination and abdominal pain, 
some differences were seen but they were not 
statistically significant within the 6 months 
according to chi-square test. 
 
CONCLUSION 
Regarding the findings of this study on 
C. mas and botanical evidence on use of this 
plant to treat the UTIs, use of C. mas tablet 
500 mg a day can decrease dysuria among 
patients with UTIs. The findings of this 
study can be an introduction to reducing the 
incidence of the recurrent UTIs and dysuria 
in patients with UTIs. Patients, especially 
those with allergy to chemical drugs, can be 
recommended to use C. mas tablet as it is 
plant-based. 
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